CSIMarket Company Name, Ticker, Competitors, else..
 
Vincerx Pharma Inc   (NASDAQ: VINC)
Other Ticker:  
 
 
Price: $0.0710 $-0.03 -29.000%
Day's High: $0.1 Week Perf: -73.21 %
Day's Low: $ 0.05 30 Day Perf: -88.74 %
Volume (M): 0 52 Wk High: $ 2.00
Volume (M$): $ 0 52 Wk Avg: $0.62
Open: $0.06 52 Wk Low: $0.05



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 2
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Vincerx Pharma Inc
Vincerx Pharma Inc is a biopharmaceutical company focused on the development and commercialization of next-generation targeted therapies for various forms of cancer. The company's mission is to provide innovative treatment options to patients with limited or no effective treatment choices. Vincerx Pharma aims to address unmet medical needs by advancing novel drug candidates through rigorous research and development processes. The company is committed to improving patient outcomes and quality of life by leveraging its expertise in precision medicine and targeted therapeutics.


   Company Address: 1825 S. Grant Street San Mateo 94402 CA
   Company Phone Number: 800-6676   Stock Exchange / Ticker: NASDAQ VINC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY      % 
EBS      % 
HCM        9.63% 
OPK        9.63% 
PFE        9.63% 
REGN        6.13% 
• View Complete Report
   



Merger and Acquisition

Vincerx Pharma?s Strategic Step into AI: A Potential Game-Changer for Cancer Treatment and Shareholder Value

Published Tue, Mar 18 2025 12:53 PM UTC

In a significant announcement for the biotechnology sector, Vincerx Pharma, Inc. (NASDAQ: VINC) has declared its entry into a non-binding letter of intent (LOI) for a business combination with Global Digital Holdings Inc., operating as QumulusAI. This development, dated March 18, 2025, represents a strategic pivot for Vincerx, a company traditionally focused on advancing nov...
Merger and Acquisition

Vincerx Pharma Terminates Reverse Merger Deal, Sets Sights on Strategic Alternatives for Growth,

Published Fri, Feb 28 2025 9:05 PM UTC

Vincerx Pharma?s Strategic Realignment: Termination of Reverse Merger Deal Sparks New OpportunitiesSAN MATEO, Calif., Feb. 28, 2025 ? Vincerx Pharma, Inc. (Nasdaq: VINC) has made...
Merger and Acquisition

Vincerx Pharma and Oqory, Inc. Join Forces: Highlighting the Promising Data for Oqory?s TROP2 Antibody-Drug Conjugate, OQY-3258,

Published Wed, Jan 29 2025 1:00 PM UTC

Vincerx Pharma and Oqory, Inc. Forge Strategic Merger to Enhance Oncology PipelineOn December 27, 2024, Vincerx Pharma, Inc. announced that it has entered into a binding term sheet for a strategic merger with Oqory, Inc., a move poised to substantially bolster Vincerx s oncology pipeline, particularly with the integration of Oqory?s promising Phase 3 TROP2 antibody-drug con...
Stock Market Announcement

Vincerx Pharma Signals Strategic Advancement with Reverse Stock Split and Oncology Partnership with Oqory, Inc.,

Published Thu, Jan 23 2025 9:05 PM UTC

Vincerx Pharma, Inc., a biopharmaceutical company committed to innovation in the treatment of hematologic and solid tumor cancers, is poised for a significant strategic transformation. On January 28, 2025, Vincerx announced a reverse stock split of its common stock. This move is set to recalibrate the company s stock fundamentals, preparing the way for future growth and inve...
Merger and Acquisition

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. to Augment Pipeline with Phase 3 TROP2 ADC.,

Published Fri, Dec 27 2024 9:05 PM UTC

Amidst a challenging landscape for biotechnology companies, Vincerx Pharma, Inc. (NASDAQ: VINC) is reportedly in discussions for a significant strategic merger with Oqory, Inc., a move that could reshape its product pipeline significantly.Vincerx, whose business model emphasizes the development and commercialization of novel small molecule drugs for cancer treatment, aims to...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com